Overall N = 78,574 | Patients with prior mAb usea N = 26,656 | Patients without prior mAb usea n = 51,918 | |
---|---|---|---|
Index medication and dose, n (%) | |||
Rimegepant | 27,140 (34.5%) | 8,465 (31.8%) | 18,675 (36.0%) |
Rimegepant 75mg | 27,140 (100.0%) | 8,465 (100.0%) | 18,675 (100.0%) |
Ubrogepant | 49,187 (62.6%) | 17,084 (64.1%) | 32,103 (61.8%) |
Ubrogepant 50mg | 33,065 (67.2%) | 10,961 (64.2%) | 22,104 (68.9%) |
Ubrogepant 100mg | 16,101 (32.7%) | 6,115 (35.8%) | 9,986 (31.1%) |
Lasmiditan | 2,247 (2.9%) | 1,107 (4.2%) | 1,140 (2.2%) |
Lasmiditan 50mg | 731 (32.5%) | 319 (28.8%) | 412 (36.1%) |
Lasmiditan 100mg | 1,513 (67.3%) | 788 (71.2%) | 725 (63.6%) |
Index nAMSM quantity dispensed | |||
Mean (SD) [median] | 9.98 (4.28) [10] | 9.97 (4.13) [10] | 9.98 (4.35) [10] |
Number of refillsb for index medication, n (%) | |||
0 refills | 27,136 (34.5%) | 7,698 (28.9%) | 19,438 (37.4%) |
1 refill | 15,152 (19.3%) | 4,996 (18.7%) | 10,156 (19.6%) |
2 refills | 11,110 (14.1%) | 3,846 (14.4%) | 7,264 (14.0%) |
3 refills | 8,378 (10.7%) | 3,141 (11.8%) | 5,237 (10.1%) |
4 + refills | 16,798 (21.4%) | 6,975 (26.2%) | 9,823 (18.9%) |
Refillsb for index therapy among patients with ≥ 1 refill | |||
Patients with ≥ 1 refill, n (%) | 51,438 (65.5%) | 18,958 (71.1%) | 32,480 (62.6%) |
Number of refills, mean (SD) [median] | 2.91 (1.94) [2] | 3.11 (2.03) [3] | 2.80 (1.88) [2] |
Days from index date to first refill, mean (SD) [median] | 53.3 (38.3) [39] | 50.3 (36.6) [37] | 55.0 (39.2) [41] |
Switch from index nAMSM to a different nAMSM | |||
Patients with ≥ 1 nAMSM switch | 8,122 (10.3%) | 4,091 (15.4%) | 4,031 (7.8%) |